Anti-Mouse CTLA-4 (CD152) [Clone UC10-4F10-11] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse CTLA-4 (CD152) [Clone UC10-4F10-11] — Purified in vivo GOLD™ Functional Grade
Product No.: C2860
Clone UC10-4F10-11 Target CTLA-4 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD152, Cytotoxic T Lymphocyte-Associated Antigen-4, Ly-56 Isotype Armenian Hamster IgG1 κ Applications FA , FC , in vivo , IP , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Armenian Hamster Recommended Isotype Controls Recommended Dilution Buffer Immunogen Purified Recombinant Mouse CTLA4 Fc Fusion Protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829616 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone UC10-4F10-11 recognizes an epitope on mouse CTLA-4. Background CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity. Antigen Distribution CTLA-4 is expressed on activated T and B lymphocytes. Ligand/Receptor CD80 (B7-1), CD86 (B7-2) Function Negative regulator of T cell activation NCBI Gene Bank ID UniProt.org Research Area Immunology . Inhibitory Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone UC10-4F10-11 is most commonly used in mice for in vivo blockade of CTLA-4 (CD152) to study immune checkpoint inhibition, promote T cell activation, and investigate mechanisms of anti-tumor immunity or immune tolerance. Key in vivo applications include:
Additional notes:
In summary, UC10-4F10-11 is a standard tool for in vivo blockade of CTLA-4 to probe immune regulation, especially in cancer immunology and tolerance models in mice. Commonly used antibodies or proteins with UC10-4F10-11 (anti-mouse CTLA-4) in immunology literature typically include:
Context and application often dictate which of these are prioritized. For example:
Summary Table: Common Co-Used Antibodies/Proteins with UC10-4F10-11
These combinations are routinely described in immunology and cancer research, and the exact panel is determined by the experimental goals. Key findings from the use of clone UC10-4F10-11 in scientific literature primarily focus on its role in blocking CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4) in mice. Here are some key points:
Overall, clone UC10-4F10-11 is a valuable tool for studying CTLA-4's role in immune regulation and its potential in cancer therapy by enhancing T cell activation and antitumor responses. Dosing regimens of clone UC10-4F10-11 vary across different mouse models based on the experimental context, disease model, and specific research objectives. The general recommended range for in vivo studies is 50–250 µg per mouse per administration, though the precise dosing depends on several factors. Common Dosing ProtocolsThe most frequently employed dosing regimen is 100 µg per mouse, administered intraperitoneally. This dose has been used successfully in multiple experimental contexts, including tumor models and immunization studies. However, the dosing frequency and duration vary significantly depending on the experimental design. Tumor ModelsIn cancer immunotherapy studies, the timing and frequency of administration are particularly important. For B16 melanoma models, the antibody was given on days 4, 7, and 10 post-tumor inoculation at 100 µg per dose. This three-dose regimen initiated shortly after tumor establishment has proven effective for inducing tumor rejection when used alone or in combination with other checkpoint inhibitors. Some studies have utilized a different approach with 20 mg/kg dosing, which translates to approximately 400-500 µg for a standard mouse weighing 20-25g. This higher dose demonstrates the flexibility in dosing strategies depending on the therapeutic goals and tumor type being studied. Immunization and Priming StudiesWhen used to modulate immune responses during T cell priming, the antibody is typically administered at 100 µg on consecutive days during the peak of T cell activation. For example, in keyhole limpet hemocyanin (KLH) immunization models, UC10-4F10-11 was given on days 3, 4, and 5 following initial immunization. This timing coincides with the upregulation of CTLA-4 expression on activated CD4+ T cells, allowing the antibody to effectively modulate the immune response during the critical priming phase. Factors Influencing Dosing DecisionsThe variation in dosing regimens reflects differences in mouse strain susceptibility, the kinetics of the disease model, and whether the antibody is used as monotherapy or in combination with other agents. When combined with other checkpoint inhibitors like anti-PD-L1, the dosing schedule must be coordinated to achieve optimal synergy, often resulting in staggered administration patterns. References & CitationsTechnical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
|---|---|
S211 | |
R1364 | |
I-140 | |
C247 | |
F1175 | |
S225 | |
A132 | |
S571 |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
